AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Imperial Brands PLC

Legal Proceedings Report Nov 16, 2018

4759_rns_2018-11-16_b5eb93c8-90cf-451c-b571-e3f5216806e0.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5496H

Imperial Brands PLC

16 November 2018

16 November 2018

Imperial Brands responds to FDA announcement

We welcome the US Food and Drug Administration's (FDA) moves to prevent youth access to tobacco and vapour products.  We share the same concerns and objectives as the FDA: the use by minors of these products is completely unacceptable. Vapour products are for adult smokers and their sale to anyone underage should be prevented. However, we also recognise the challenge faced by the FDA in balancing concerns regarding youth appeal and access, given the positive public health potential of vapour products.

We believe that through our blu product range we offer adult smokers a significantly better alternative than combustible cigarettes and consistently reinforce this message, while at the same time working actively against youth access to, and usage of, our products.

On the FDA's specific actions, we welcome its commitment to standards for effective age verification for all online sales of vapour products; a technology which we already use on blu.com.

We recognise the FDA's concern over age verification at brick-and-mortar retail outlets and will consider further appropriate actions. The availability of quality vaping products like blu in outlets where tobacco products are sold is vital to help adults transition away from combustible tobacco.

We are developing a connected version of myblu with device locking technology and are greatly encouraged by Commissioner Gottlieb's comment on a process to accelerate development and review of vapour products with child protection features.

We also note today the FDA's proposals regarding menthol cigarettes and flavoured cigars, which would need to be supported by the relevant science and other evidence. Such proposals are likely to require a multi-year process, in which we will be fully engaged.

ENDS

Investor Contacts Media Contacts
Peter Durman +44 (0)7970 328 903 Alex Parsons +44 (0)7967 467 241
Matt Sharff +44 (0)7964 110 921 Simon Evans +44 (0)7967 467 684
Mat Slade +44 (0)7811 974 438

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

STRGGGQPGUPRGBA

Talk to a Data Expert

Have a question? We'll get back to you promptly.